- Report
- August 2022
- 30 Pages
Global
From €3101EUR$3,250USD£2,638GBP
- Report
- February 2021
- 30 Pages
Global
From €3101EUR$3,250USD£2,638GBP
- Report
- February 2021
- 30 Pages
Global
From €3101EUR$3,250USD£2,638GBP
- Report
- February 2021
- 30 Pages
Global
From €3101EUR$3,250USD£2,638GBP
- Report
- February 2021
- 30 Pages
Global
From €3101EUR$3,250USD£2,638GBP
- Report
- February 2021
- 30 Pages
Global
From €3101EUR$3,250USD£2,638GBP
- Report
- February 2021
- 30 Pages
Global
From €3101EUR$3,250USD£2,638GBP
- Report
- February 2021
- 30 Pages
Global
From €3101EUR$3,250USD£2,638GBP
- Report
- January 2022
- 60 Pages
Global
From €3769EUR$3,950USD£3,206GBP
- Report
- September 2022
- 155 Pages
Global
From €4055EUR$4,250USD£3,450GBP
- Report
- August 2018
- 108 Pages
Global
From €4246EUR$4,450USD£3,612GBP
- Report
- February 2019
- 156 Pages
Global
From €2862EUR$3,000USD£2,435GBP
- Report
- November 2018
- 11 Pages
Europe
From €2858EUR$2,995USD£2,431GBP
- Report
- November 2018
- 125 Pages
Europe
From €2862EUR$3,000USD£2,435GBP
- Report
- November 2018
- 46 Pages
Global
From €2858EUR$2,995USD£2,431GBP
- Report
- February 2018
- 135 Pages
Global
From €4771EUR$5,000USD£4,059GBP
- Report
- January 2018
- 59 Pages
Global
From €2858EUR$2,995USD£2,431GBP
- Report
- March 2023
- 171 Pages
Global
From €2385EUR$2,500USD£2,029GBP
- Report
- December 2021
- 120 Pages
Global
From €2385EUR$2,500USD£2,029GBP
- Report
- August 2021
Global
From €4761EUR$4,990USD£4,050GBP
The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them.
The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives.
Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more